Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T20:11:21.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    A banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology. The site revision changes from v3.7.1 to v3.7.2 while the study page remains an error page.
    Difference
    1%
    Check dated 2026-10-20T21:40:50.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1, while the page continues to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-06T20:55:01.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study content and preventing access to the study details.
    Difference
    17%
    Check dated 2026-09-22T22:22:03.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The revision indicator updated from v3.6.6 to v3.7.0, signaling a new site build with behind-the-scenes updates and bug fixes rather than changes to study data.
    Difference
    0.1%
    Check dated 2026-09-15T20:45:48.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The page's footer revision was updated from v3.6.5 to v3.6.6, representing a maintenance/template update. It does not change the study content or how users interact with the page.
    Difference
    0.1%
    Check dated 2026-09-01T19:15:53.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.